Barriers to compliance with prophylaxis therapy in haemophilia
- PMID: 11442644
- DOI: 10.1046/j.1365-2516.2001.00534.x
Barriers to compliance with prophylaxis therapy in haemophilia
Abstract
Prophylaxis, or the practice of routine replacement infusions of clotting factor concentrate in persons with severe haemophilia, is a demanding medical regimen. Prophylactic infusions require direct venepuncture or sterile entry into a central venous access device on a regular basis. A telephone survey was conducted to elicit information regarding the barriers to compliance with prophylaxis. The Mountain States Regional Haemophilia and Thrombosis Center has recommended prophylaxis to 52 male patients with haemophilia A or B. The haemophilia nurse attempted to contact all of these patients or their parents, and contact was made with 38 (73.1%) of them. Respondents were asked about the following issues: their decision to initiate prophylaxis; their self-rated compliance; the challenges, barriers, and facilitators of prophylaxis; and their perceived value of the therapy. Four patients (10.5%) elected not to begin prophylaxis. Of the 34 persons who began prophylaxis, 20 respondents (58.8%) rated their compliance as excellent. Nearly one-third of the families with excellent compliance (giving 75-100% of prescribed infusions) stated that the time-consuming nature of prophylaxis was the most significant challenge of the regimen. In addition, 58.3% of the families that gave less than the prescribed number of infusions reported that the time commitment was the primary reason for missing infusions. Knowledge of the benefits of prophylaxis was the primary facilitator of compliance for 44.1% of families. Ninety-seven percent of respondents rated prophylaxis as very valuable. These data show that despite the known benefits of prophylaxis, it is a demanding medical regimen, and compliance is imperfect. In addition, this study underscores the importance of providing continuing support and education for patients and families who are implementing prophylaxis.
Similar articles
-
Optimizing factor prophylaxis for the haemophilia population: where do we stand?Haemophilia. 2004 Oct;10 Suppl 4:97-104. doi: 10.1111/j.1365-2516.2004.00998.x. Haemophilia. 2004. PMID: 15479380 Review.
-
A comparison of traditional vs. Canadian tailored prophylaxis dosing of prophylactic factor infusions in children with haemophilia A and B in a single hemophilia treatment center.Haemophilia. 2012 Jul;18(4):561-7. doi: 10.1111/j.1365-2516.2011.02741.x. Epub 2012 Jan 5. Haemophilia. 2012. PMID: 22221939
-
Physicians' perceptions of adherence to prophylactic clotting factor infusions.Haemophilia. 2008 Jan;14(1):25-9. doi: 10.1111/j.1365-2516.2007.01591.x. Epub 2007 Nov 20. Haemophilia. 2008. PMID: 18028395
-
Devising a best practice approach to prophylaxis in boys with severe haemophilia: evaluation of current treatment strategies.Haemophilia. 2010 Mar;16 Suppl 2:4-9. doi: 10.1111/j.1365-2516.2009.02196.x. Haemophilia. 2010. PMID: 20132332
-
Prophylaxis in the haemophilia population.Haemophilia. 2010 Jul;16 Suppl 5:181-8. doi: 10.1111/j.1365-2516.2010.02318.x. Haemophilia. 2010. PMID: 20590879 Review.
Cited by
-
Protein S antibody as an adjunct therapy for hemophilia B.Blood Adv. 2024 Jan 23;8(2):441-452. doi: 10.1182/bloodadvances.2023010819. Blood Adv. 2024. PMID: 37773781 Free PMC article.
-
Adherence to hemophilia patients with prophylaxis: Veritas-Pro and psychometric properties adapted to Turkish.PLoS One. 2023 Aug 9;18(8):e0288625. doi: 10.1371/journal.pone.0288625. eCollection 2023. PLoS One. 2023. PMID: 37556439 Free PMC article.
-
Patient perspectives regarding gene therapy in haemophilia: Interviews from the PAVING study.Haemophilia. 2021 Jan;27(1):129-136. doi: 10.1111/hae.14190. Epub 2020 Nov 7. Haemophilia. 2021. PMID: 33161616 Free PMC article.
-
Adherence and Quality of Life in Adult Patients With Haemophilia A, Haemophilia B and Von Willebrand Disease: A National Cross-Sectional Survey.Eur J Haematol. 2025 Jan;114(1):164-172. doi: 10.1111/ejh.14324. Epub 2024 Oct 10. Eur J Haematol. 2025. PMID: 39390782 Free PMC article.
-
Emerging Therapies in Hemophilia: Improving Equitable Access to Care.J Blood Med. 2025 Feb 20;16:95-115. doi: 10.2147/JBM.S490588. eCollection 2025. J Blood Med. 2025. PMID: 39995897 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical